Patents Assigned to Universitatsklinikum Freiburg
  • Patent number: 10426511
    Abstract: A device for detaching parietal thrombi from a bodily vessel is described having a catheter including at least one catheter section with a catheter wall with at least one wall opening which passes completely through the catheter wall. The catheter wall along the least one catheter section is made of a resiliently deformable material in which the at least one wall opening includes a separating helical gap wound around the catheter wall at least in parts along the catheter section. A fixing device permits releasable fixing of the catheter on a bodily vessel so that the catheter can be converted, exclusively by an external mechanical constraint in the form of a torque acting torsionally on the catheter, from a state of smaller catheter outer diameter to a state of larger catheter outer diameter.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: October 1, 2019
    Assignee: UNIVERSITÄTSKLINIKUM FREIBURG
    Inventor: Christoph Hehrlein
  • Patent number: 10420581
    Abstract: A device for detaching parietal thrombi from a blood vessel is disclosed, comprising a catheter including at least one catheter section, wherein an outer diameter of the at least one catheter section is changeable and at least one wall opening extends transversely through a wall of the at least one catheter section. The catheter wall along the at least one catheter section is a resilient and deformable material. The catheter is transformed from a smaller catheter outer diameter to a uniform larger catheter outer diameter by a resilient change in shape. A displacement body can be introduced into the at least one catheter section which is transformed in diameter to deform the catheter from the smaller catheter outer diameter to the larger outer diameter for capturing thrombus material.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: September 24, 2019
    Assignee: UNIVERSITATSKLINIKUM FREIBURG
    Inventor: Christoph Hehrlein
  • Patent number: 10357537
    Abstract: The present invention relates to a pharmaceutical composition comprising a cyclotide for use in immune suppression as well as to a method for immune suppression comprising the step of administering an effective amount of a pharmaceutical composition comprising such a cyclotide to a subject in need thereof. The present invention also relates to a pharmaceutical composition comprising a cyclotide for use in treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation. Likewise, the present invention also relates to a method for treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: July 23, 2019
    Assignees: Medizinische Universitat Wien, Universitatsklinikum Freiburg
    Inventors: Christian Werner Gruber, Carsten Gruendemann
  • Patent number: 10259915
    Abstract: The present invention relates to substrates comprising a crosslinked network of covalently attached antimicrobial and/or antibiofouling polymers. The crosslinked network of antimicrobial and/or antibiofouling polymers acts highly efficiently against pathogens, e.g. bacteria and fungi. Both the antimicrobial and the antibiofouling cross-linked polymer networks are preferably better resistant to mechanical damage than simple surface-immobilized polymer monolayers. The antimicrobial and/or antibiofouling polymers of the crosslinked network are preferably obtained by ring opening metathesis polymerization (ROMP) and exhibit a molecular weight of preferably more than 30,000 or even 100,000 g mol?1. The crosslinked network of antimicrobial and/or antibiofouling polymers is preferably covalently attached to the surface of a substrate, e.g. an implant, a medical device, medical equipment or a (tissue-supporting) biomaterial, etc.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: April 16, 2019
    Assignees: UNIVERSITATSKLINIKUM FREIBURG, ALBERT-LUDWIGS-UNIVERSITAT FREIBURG
    Inventors: Karen Lienkamp, Jakob Belardi, Peng Zou, Ali Al-Ahmad, Thorsten Steinberg, Pascal Tomakidi
  • Patent number: 10159710
    Abstract: The present invention relates to a pharmaceutical composition comprising a cyclotide for use in immune suppression as well as to a method for immune suppression comprising the step of administering an effective amount of a pharmaceutical composition comprising such a cyclotide to a subject in need thereof. The present invention also relates to a pharmaceutical composition comprising a cyclotide for use in treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation. Likewise, the present invention also relates to a method for treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: December 25, 2018
    Assignees: Universitatsklinikum Freiburg, Medizinische Universitat Wien
    Inventors: Christian Werner Gruber, Carsten Gruendemann
  • Patent number: 9995807
    Abstract: In a control method and control unit to monitor a data acquisition of magnetic resonance image data of an imaging area located in a measurement volume of a magnetic resonance apparatus, an RF excitation pulse is radiated by an RF transmission/reception device of the magnetic resonance apparatus, raw data are acquired after a time after the radiated excitation pulse, by means of the RF transmission/reception device, and store the raw data, the raw data are transmitted to a monitoring unit and (a) through (c) are repeated while switching different gradients for spatial coding by readout of k-space corresponding to the imaging area along trajectories that are predetermined by the switched gradients, up to a termination criterion that is predetermined by the monitoring unit.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: June 12, 2018
    Assignees: Siemens Aktiengesellschaft, Universitatsklinikum Freiburg
    Inventors: Guobin Li, Dominik Paul
  • Patent number: 9957544
    Abstract: The present invention relates to a device comprising a sample receiving appliance, a receiving appliance for test organisms, preferably for a suspension comprising test organisms, in particular for a bacterial suspension, and a jet pump appliance, wherein the jet pump appliance is, or can be brought, into active connection with the receiving appliance, and wherein the jet pump appliance is designed and installed in order, by means of a propellant medium having a higher pressure than atmospheric pressure at the location of installation of the device to spray test organisms in the form of an aerosol in the direction of the sample receiving installation, wherein the device has an installation for controlling a reproducible pressure of the propellant medium during the spraying of the test organisms and also the use of a device according to the invention.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: May 1, 2018
    Assignee: UNIVERSITATSKLINIKUM FREIBURG
    Inventors: Thorsten Steinberg, Ali Al-Ahmad, Karen Lienkamp, Norbert Nanko
  • Patent number: 9808522
    Abstract: The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: November 7, 2017
    Assignees: UNIVERSITATSKLINIKUM FREIBURG, BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LTD.
    Inventors: Andreas Zirlik, Dennis Wolf, Karlheinz Peter
  • Patent number: 9796744
    Abstract: The present invention generally relates to the field of detecting and preventing infectious diseases caused by Enterococcus faecalis and/or Enterococcus faecium.
    Type: Grant
    Filed: November 13, 2007
    Date of Patent: October 24, 2017
    Assignee: UNIVERSITÄTSKLINIKUM FREIBURG
    Inventors: Johannes Hübner, Otto Holst, Christian Theilacker, Zbigniew Kaczynski
  • Patent number: 9453052
    Abstract: The present invention relates to a pharmaceutical composition comprising a cyclotide for use in immune suppression as well as to a method for immune suppression comprising the step of administering an effective amount of a pharmaceutical composition comprising such a cyclotide to a subject in need thereof. The present invention also relates to a pharmaceutical composition comprising a cyclotide for use in treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation. Likewise, the present invention also relates to a method for treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: September 27, 2016
    Assignees: Universitatsklinikum Freiburg, Medizinische Universitat Wien
    Inventors: Christian Werner Gruber, Carsten Gruendemann
  • Patent number: 9290531
    Abstract: The present invention relates to synthetic lipoteicoic acid (LTA) mimetics which are useful as vaccine components for therapy and/or prophylaxis of bacterial infection.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: March 22, 2016
    Assignee: UNIVERSITÄTSKLINIKUM FREIBURG
    Inventors: Johannes Huebner, Andrea Huebner-Kropec, Jeroen Dirk Cornelis Codée, Gijsbert Arie Van Der Marel, Wouter Frederick Johan Hogendorf
  • Patent number: 9278097
    Abstract: The invention provides a medication for the prophylaxis and/or therapy against diseases or complications in connection with portal hypertension, particularly against bleeding complications.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: March 8, 2016
    Assignee: Universitatsklinikum Freiburg
    Inventors: Wolfgang Kreisel, Peter Deibert
  • Patent number: 9238694
    Abstract: Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: January 19, 2016
    Assignee: UNIVERSITÄTSKLINIKUM FREIBURG
    Inventors: Ursula Elsässer-Beile, Philipp Wolf, Dorothee Gierschner, Patrick Bühler, Ulrich Wetterauer
  • Patent number: 9005622
    Abstract: The present invention relates to enterococcal cell wall components and their uses in the prevention and therapy of bacterial infection.
    Type: Grant
    Filed: January 19, 2010
    Date of Patent: April 14, 2015
    Assignees: Forschungszentrum Borstel, Universitätsklinikum Freiburg
    Inventors: Johannes Hübner, Christian Theilacker, Otto Holst, Zbigniew Kaczynski
  • Publication number: 20150025168
    Abstract: The present invention relates to substrates comprising a crosslinked network of covalently attached antimicrobial and/or antibiofouling polymers. The crosslinked network of antimicrobial and/or antibiofouling polymers acts highly efficiently against pathogens, e.g. bacteria and fungi. Both the antimicrobial and the antibiofouling cross-linked polymer networks are preferably better resistant to mechanical damage than simple surface-immobilized polymer monolayers. The antimicrobial and/or antibiofouling polymers of the crosslinked network are preferably obtained by ring opening metathesis polymerization (ROMP) and exhibit a molecular weight of preferably more than 30,000 or even 100,000 g mol?1. The crosslinked network of antimicrobial and/or antibiofouling polymers is preferably covalently attached to the surface of a substrate, e.g. an implant, a medical device, medical equipment or a (tissue-supporting) biomaterial, etc.
    Type: Application
    Filed: March 8, 2013
    Publication date: January 22, 2015
    Applicant: Universitatsklinikum Freiburg
    Inventors: Karen Lienkamp, Jakob Belardi, Peng Zou, Ali Al-Ahmad, Thorsten Steinberg, Pascal Tomakidi
  • Patent number: 8835115
    Abstract: The present disclosure provides methods of identifying subjects having an increased likelihood of developing one or more adverse side effects resulting from administration of a microtubule-stabilizing agent. In particular examples, the method includes determining whether the subject has an ABCB1 predictive polymorphism for microtubule-stabilizing agent-induced toxicity, wherein the presence of such a polymorphism indicates that the subject has an increased risk of developing microtubule-stabilizing agent induced adverse effects. Examples of ABCB1 predictive polymorphisms include 2677G>T/A and 3435C>T. Also provided are methods of modifying microtubule-stabilizing agent therapy in a subject identified as having one or more ABCB1 predictive polymorphisms. Kits and isolated nucleic acid molecules that can be used in the disclosed methods are also provided.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: September 16, 2014
    Assignees: The United States of America as represented by the Secretary, Department of Health and Human Services, Universitätsklinikum Freiburg
    Inventors: William D. Figg, Klaus Mross, Dirk Behringer, Alex Sparreboom, Tristan Sissung, Stephan Mielke
  • Publication number: 20140155583
    Abstract: Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody.
    Type: Application
    Filed: December 13, 2013
    Publication date: June 5, 2014
    Applicant: UNIVERSITÄTSKLINIKUM FREIBURG
    Inventors: Ursula Elsässer-Beile, Philipp Wolf, Dorothee Gierschner, Patrick Bühler, Ulrich Wetterauer
  • Patent number: 8741302
    Abstract: A medicament for the treatment or the prevention of a bacterial infection is disclosed which contains a polypeptide having a contiguous sequence of at least six amino acids of SEQ ID NO:1. Said polypeptide can be used for the preparation of a vaccine against an Enterococcus infection.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: June 3, 2014
    Assignee: Universitatsklinikum Freiburg
    Inventors: Johannes Huebner, Andrea Kropec-Huebner, Irina Sava
  • Publication number: 20140147445
    Abstract: The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.
    Type: Application
    Filed: August 17, 2011
    Publication date: May 29, 2014
    Applicants: BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LTD., UNIVERSITATSKLINIKUM FREIBURG
    Inventors: Andreas Zirlik, Dennis Wolf, Karlheinz Peter
  • Publication number: 20140050741
    Abstract: The present invention relates to synthetic lipoteicoic acid (LTA) mimetics which are useful as vaccine components for therapy and/or prophylaxis of bacterial infection.
    Type: Application
    Filed: February 17, 2012
    Publication date: February 20, 2014
    Applicants: UNIVERSITEIT LEIDEN, UNIVERSITÄTSKLINIKUM FREIBURG
    Inventors: Johannes Huebner, Andrea Huebner-Kropec, Jeroen Dirk Cornelis Codée, Gijsbert Arie Van Der Marel, Wouter Frederick Johan Hogendorf